Results 1-25 of 25 (Search time: 0.018 seconds).
Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link | |
---|---|---|---|---|---|---|---|
1 | 2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
2 | 2011 | Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study | Ch'Ang H.-J.; Lin Y.-L.; HSIU-PO WANG ; Chiu Y.-F.; MING-CHU CHANG ; CHIH-HUNG HSU ; YU-WEN TIEN ; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG ; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. | International Journal of Radiation Oncology Biology Physics | 19 | 17 | |
3 | 2011 | IκB kinases increase Myc protein stability and enhance progression of breast cancer cells | Yeh P.-Y.; YEN-SHEN LU ; DA-LIANG OU ; ANN-LII CHENG | Molecular Cancer | 24 | 23 | |
4 | 2011 | Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers | Ho Y.-F.; Lu W.-C.; Chen R.R.-L.; ANN-LII CHENG ; KUN-HUEI YEH | Anti-Cancer Drugs | 5 | 3 | |
5 | 2011 | T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement | SUNG-HSIN KUO ; ANN-LII CHENG ; CHUNG-WU LIN ; CHIH-HUNG HSU ; MING-SHIANG WU ; KUN-HUEI YEH ; Tzeng Y.-S.; Chen L.-T. | Cancer Chemotherapy and Pharmacology | 13 | 8 | |
6 | 2011 | Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter Pylori-independent gastric MALT lymphoma | SUNG-HSIN KUO ; Weng W.-H.; Chen Z.-H.; PING-NING HSU ; MING-SHIANG WU ; CHUNG-WU LIN ; Jeng H.-J.; KUN-HUEI YEH ; Tsai H.-J.; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 7 | 9 | |
7 | 2011 | A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan | Chen J.-S.; Chao Y.; Hsieh R.-K.; ANN-LII CHENG ; Chen P.-M.; Chiou T.-J.; Chao T.-Y.; KUN-HUEI YEH ; Chen L.-T.; Whang-Peng J. | Cancer Chemotherapy and Pharmacology | 6 | 5 | |
8 | 2011 | Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells | Rodriguez B.A.T.; Weng Y.-I.; Liu T.-M.; Zuo T.; Hsu P.-Y.; CHING-HUNG LIN ; ANN-LII CHENG ; Cui H.; Yan P.S.; Huang T.H.-M. | Carcinogenesis | 40 | 35 | |
9 | 2011 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; HSIANG-PO HUANG ; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 146 | 140 | |
10 | 2011 | Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf | Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; ANN-LII CHENG ; PEI-JER CHEN ; Shiau C.-W. | European Journal of Medicinal Chemistry | 32 | 29 | |
11 | 2011 | Prognostic molecular markers in Women aged 35 years or younger with breast cancer: Is there a difference from the older patients? | CHING-HUNG LIN ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; KUAN-TING KUO ; Wang C.-C.; You S.-L.; PO-HAN LIN ; DWANG-YING CHANG ; WEN-HUNG KUO ; KING-JEN CHANG ; ANN-LII CHENG | Journal of Clinical Pathology | 8 | 8 | |
12 | 2011 | Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 | SUNG-HSIN KUO ; CHIH-HUNG HSU ; Chen L.-T.; YEN-SHEN LU ; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH ; ANN-LII CHENG | European Journal of Cancer | 17 | 17 | |
13 | 2011 | Recent advances in the treatment of metastatic colorectal cancer in Taiwan | Lin Y.-L.; KUN-HUEI YEH ; ANN-LII CHENG | Journal of the Formosan Medical Association | 1 | 1 | |
14 | 2011 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | CHAO-YU HSU ; Ying-Chun Shen ; CHIH-WEI YU ; CHIUN HSU ; Hu F.-C.; CHIH-HUNG HSU ; BANG-BIN CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Journal of Hepatology | 106 | 100 | |
15 | 2011 | Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials | SHIH-HUNG YANG ; Kuo Y.-H.; YU-WEN TIEN ; CHIUN HSU ; CHIH-HUNG HSU ; SUNG-HSIN KUO ; ANN-LII CHENG | Oncology | 13 | 13 | |
16 | 2011 | Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy | YU-YUN SHAO ; LI-CHUN LU ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 34 | 28 | |
17 | 2011 | Antiangiogenic strategies for the treatment of hepatocellular carcinoma | CHIUN HSU ; Ying-Chun Shen ; ANN-LII CHENG | Targeted Therapies for Hepatocellular Carcinoma | 0 | 0 | |
18 | 2011 | Needs for hepatocellular carcinoma control policy in the Asia-Pacific region | Bridges J.F.P.; Joy S..; Gallego G.; Kudo M.; Ye S.-L.; Han K.-H.; ANN-LII CHENG ; Blauvelt B. | Asian Pacific Journal of Cancer Prevention | 25 | ||
19 | 2011 | Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; PEI-JER CHEN ; ZHONG-ZHE LIN ; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | ||
20 | 2011 | Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia | Han K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG | Oncology | 98 | 98 | |
21 | 2011 | Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib | Harmon C.S.; DePrimo S.E.; Raymond E.; ANN-LII CHENG ; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Lechuga M.J.; Lanzalone S.; Lin X.; Faivre S. | Journal of Translational Medicine | 21 | 20 | |
22 | 2011 | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A | Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; PEI-JER CHEN ; ANN-LII CHENG | Molecular Cancer Therapeutics | 36 | 32 | |
23 | 2011 | Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells | Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; CHIH-HUNG HSU ; PEI-JER CHEN ; ANN-LII CHENG | Journal of Pharmacology and Experimental Therapeutics | 265 | 254 | |
24 | 2011 | Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib | Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG ; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E. | Clinical Cancer Research | 73 | 67 | |
25 | 2011 | Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era | I-CHUN CHEN ; CHING-HUNG LIN ; CHIUN-SHENG HUANG ; HUANG-CHUN LIEN ; CHIUN HSU ; WEN-HUNG KUO ; YEN-SHEN LU ; ANN-LII CHENG | Breast Cancer Research and Treatment | 87 | 74 |